bioAffinity Technologies, Inc. (BIAF)
(Delayed Data from NSDQ)
$0.30 USD
-0.01 (-1.94%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.30 0.00 (0.67%) 4:44 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Return on Equity (TTM)
bioAffinity Technologies, Inc.'s return on equity, or ROE, is -367.64% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that BIAF has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
BIAF 0.30 -0.01(-1.94%)
Will BIAF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIAF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIAF
The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies
Top Research Reports for Meta Platforms, ServiceNow & Booking
BIAF: What are Zacks experts saying now?
Zacks Private Portfolio Services
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa
Other News for BIAF
BIAF Gains Canadian Patent for Innovative Lung Disease Detection Method | BIAF Stock News
BioAffinity Technologies awarded new Canadian patent for CyPath Lung